Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study.
作者
Jean‐Pascal Machiels,Lisa Francesca Licitra,Yungan Tao,Chia‐Jui Yen,Danny Rischin,John N. Waldron,Barbara Ann Burtness,Vincent Grégoire,Sanjiv S. Agarwala,Jeffrey Thomas Yorio,Jean‐Pierre Delord,Sercan Aksoy,Sadakatsu Ikeda,Ruey‐Long Hong,Joy Yang Ge,Holly M. Brown,Behzad Bidadi,Lillian L. Siu
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins] 日期:2018-05-20卷期号:36 (15_suppl): TPS6094-TPS6094被引量:6
标识
DOI:10.1200/jco.2018.36.15_suppl.tps6094
摘要
TPS6094 Background: Preclinical data in murine cancer models show improved tumor growth control and survival when radiation therapy (RT) is combined with a PD-1 inhibitor. Pembrolizumab is effective for treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), and initial results from a phase 1b study suggest that pembrolizumab plus chemoradiation therapy (CRT) is tolerable in patients with locally advanced (LA) HNSCC. KEYNOTE-412 (NCT03040999) is a phase 3, randomized, placebo-controlled, double-blind trial to determine efficacy and safety of pembrolizumab given with CRT and as maintenance therapy vs placebo plus CRT in LA-HNSCC. Methods: Patients will be randomly assigned (1:1) to receive pembrolizumab 200 mg every 3 weeks plus cisplatin-based CRT or placebo plus cisplatin-based CRT. Treatment will be stratified by RT regimen (accelerated RT [56-70 Gy, 6 fractions/week for 6 weeks] or standard RT [56-70 Gy, 5 fractions/week for 7 weeks]), tumor site/p16 status (oropharynx p16 positive vs p16 negative or larynx/hypopharynx/oral cavity), and disease stage (III vs IV). Priming dose of pembrolizumab or placebo will be given 1 week before CRT, followed by 2 doses during CRT, and an additional 14 doses after CRT, for a total of 17 pembrolizumab or placebo infusions. Eligibility criteria include age ≥18 years; newly diagnosed, treatment-naive, oropharyngeal p16–positive (any T4 or N3), oropharyngeal p16–negative (any T3-T4 or N2a-N3), or larynx/hypopharynx/oral cavity (any T3-T4 or N2a-N3) SCC; evaluable tumor burden (RECIST v1.1); and ECOG performance status 0-1. Treatment will be discontinued at the time of centrally confirmed disease progression, unacceptable toxicity, or patient/physician decision to withdraw. Patients will be evaluated to determine the necessity of neck dissection 12 weeks after completion of CRT. The primary end point is event-free survival. Secondary end points are overall survival, safety, and patient-reported outcomes. Relationship between biomarkers and clinical activity will be included as an exploratory end point. Recruitment is ongoing in 21 countries and will continue until ~780 patients are enrolled. Clinical trial information: NCT03040999.